Tezspire shown to be effective across broad population of severe asthma patients

28 February 2022

Further data has been presented on AstraZeneca (LSE: AZN) and Amgen’s (Nasdaq: AMGN) Tezspire (tezepelumab), which was recently approved in the USA for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

Results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed that Tezspire demonstrated reductions in the annualized asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.

"Potential to reduce severe asthma exacerbations in patients irrespective of biomarker levels and seasonal triggers"These findings, which were presented at the 2022 AAAAI Annual Meeting, support the role of Tezspire as a first-in-class treatment for a broad population of patients with severe asthma, irrespective of biomarker levels.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK